Günter Schneider
@schneiderg.bsky.social
📤 202
📥 166
📝 11
PhD position available in pancreatic cancer research (
chirurgie.umg.eu/forschung/ag...
). Project focus: splicing as a therapeutic vulnerability, integrating functional genomics and mechanistic biology with translational models. If you’re interested, please send CV and motivation letter.
loading . . .
AG Schneider EN | Universitätsmedizin Göttingen
https://chirurgie.umg.eu/forschung/ag-schneider-en/
20 days ago
0
1
1
reposted by
Günter Schneider
Lyssiotis Lab
6 months ago
Our department is recruiting a new tenure track Assistant/Associate Professor. Come join the #1 physiology department in the country and some awesome colleagues doing high impact science and training the next generation of scientists
jobs.sciencecareers.org/job/674815/a...
loading . . .
Assistant/Associate Professor - Tenure Track - Physiology - University of Michigan, Ann Arbor job with University of Michigan Department of Molecular & Integrative Physiology | 674815
Tenure track assistant/associate professor in the Department of Molecular & Integrative Physiology at the University of Michigan Medical School.
https://jobs.sciencecareers.org/job/674815/assistant-associate-professor-tenure-track-physiology/
0
23
17
reposted by
Günter Schneider
6 months ago
Honored to give the closing talk at the inaugural
#GordonResearchConference
(#GRC) on
#Microproteins
tomorrow in Castelldefels, Spain. Excited to share our latest work on developing a clinically viable MYC inhibitor and wrap up an incredible week of cutting-edge science.
@vhio.bsky.social
#peptomyc
0
1
2
reposted by
Günter Schneider
Kusterlab
7 months ago
Excited to share our latest work published in
#ScienceSignaling
! 🚀
www.science.org/doi/10.1126/...
(1/4)
loading . . .
Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Proteomic analyses offer insights into how KRAS inhibitors affect oncogenic KRAS signaling.
https://www.science.org/doi/10.1126/scisignal.adt6552
3
41
13
reposted by
Günter Schneider
Quinn Sievers
7 months ago
www.science.org/doi/10.1126/...
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors | Science
loading . . .
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors
Mutant RAS proteins are among the most prevalent drivers of human cancer, and the glycine to aspartic acid mutation at codon 12 (G12D) is the most common variant. Mutation-selective covalent inhibitor...
https://www.science.org/doi/10.1126/science.ads0239
0
10
3
reposted by
Günter Schneider
Lyssiotis Lab
7 months ago
So grateful and excited to partner with the Stephenson Global Pancreatic Cancer Research Institute to advance our collaborative program targeting lysosome and Kras metabolism in pancreatic cancer!
michmed.org/rwVDK
loading . . .
Lyssiotis awarded Stephenson Global Scholar Grant for pancreatic cancer research
Costas Lyssiotis, Ph.D., co-director of the Rogel and Blondy Center for Pancreatic Cancer at the Rogel Cancer Center, was one of six researchers to receive inaugural grants from the Stephenson Global ...
https://michmed.org/rwVDK
3
32
3
Opening!
9 months ago
0
3
0
Soon starting!
10 months ago
0
1
0
#pancreaticcancer
- potential of PRMT5 inhibitors
#collateral
vulnerability
www.sciencedirect.com/science/arti...
loading . . .
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by mutations in the Kirsten rat sarcoma virus (KRAS) oncogene. Due to the pivotal role…
https://www.sciencedirect.com/science/article/pii/S193652332500097X
11 months ago
0
1
0
reposted by
Günter Schneider
KFO 5002
about 1 year ago
Hello! We are
#NewHere
. The KFO 5002 is a clinical research group at the University Medical Center Göttingen and funded by the DFG. Our research focuses on 'Deciphering Genome Dynamics for Subtype-specific Therapy in
#PancreaticCancer
'. Currently in our second funding period!
1
6
4
reposted by
Günter Schneider
We’re hiring! Postdoc position available to explore therapy tolerance and resistance in
#PDAC
cells. Join us and make an impact! Apply:
umg.recruiting-portal.com/r/z113b9i314...
#CancerResearch
#PancreaticCancer
loading . . .
Klinik für Allgemein-, Viszeral- und Kinderchirurgie -- Postdoctoral Scientist Position (f/m/d)
Postdoctoral Scientist Position (f/m/d)
https://umg.recruiting-portal.com/r/z113b9i314h07xx/Postdoctoral+Scientist+Position+fmd/37075/G%C3%B6ttingen
about 1 year ago
0
2
1
Thanks Tamara, Christine, Channing & Björn! Important overview!
#KRAS
www.cell.com/trends/cance...
loading . . .
KRAS inhibitors: resistance drivers and combinatorial strategies
In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRASG12C inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively. However, rather than marking the end of a successful assault on the Mount Everest of cancer research, this landmark only revealed new challenges in RAS drug discovery. In this review, we highlight the progress on defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS therapies.
https://www.cell.com/trends/cancer/fulltext/S2405-8033%2824%2900275-9
about 1 year ago
0
8
2
reposted by
Günter Schneider
Norbert Kraut
about 1 year ago
Hot off the press: Our work with
#KRASmulti
inhibitors suggests novel therapeutic concept for
#cancers
harboring
#KRAS
amplifications. Just published by our team at Boehringer Ingelheim in
@theaacr.bsky.social
journal Molecular Cancer Therapeutics.
aacrjournals.org/mct/article/...
1
11
3
reposted by
Günter Schneider
Itai Yanai
about 1 year ago
Some papers are very difficult to read but that doesn’t necessarily mean they're deeper than other papers. Authors must work very hard to make their story easy to read and understand by others. Or as Stephen King says: "the shorter the book, the less bullshit".
0
90
10
reposted by
Günter Schneider
Laura Lorenzo-Sanz
over 1 year ago
Extremely happy to share my first-author paper out in
#NatureCommunications
dissecting how the epithelial-mesenchymal plasticity of cancer cells influences immunotherapy response!
@natureportfolio.bsky.social
➡️
www.nature.com/articles/s41...
loading . . .
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma - Nature Communications
Immune surveillance is critical to prevent the development and progression of cutaneous squamous cell carcinoma (cSCC). Here, the authors show that epithelial-mesenchymal plasticity in cancer cells is...
https://www.nature.com/articles/s41467-024-49718-8
3
105
9
We’re hiring! Postdoc position available to explore therapy tolerance and resistance in
#PDAC
cells. Join us and make an impact! Apply:
umg.recruiting-portal.com/r/z113b9i314...
#CancerResearch
#PancreaticCancer
loading . . .
Klinik für Allgemein-, Viszeral- und Kinderchirurgie -- Postdoctoral Scientist Position (f/m/d)
Postdoctoral Scientist Position (f/m/d)
https://umg.recruiting-portal.com/r/z113b9i314h07xx/Postdoctoral+Scientist+Position+fmd/37075/G%C3%B6ttingen
about 1 year ago
0
2
1
@maxreichertmd.bsky.social
Welcome Max!
about 1 year ago
0
2
0
reposted by
Günter Schneider
Hans Clevers
about 1 year ago
Exciting study by Amanda Andersson Rolf et al: In vitro expansion of a human fetal
#pancreas
#stemcell
that generates all three pancreatic cell lineages”.
www.cell.com/cell/fulltex...
New
#organoid
protocol allows the seemingly indefinite expansion of human fetal pancreatic Lgr5+ stem cell 1/
loading . . .
Long-term in vitro expansion of a human fetal pancreas stem cell that generates all three pancreatic cell lineages
Identification of an LGR5 as a marker for a tripotent stem/progenitor cell of the human fetal pancreas. Organoids derived from single LGR5+ cells are capable of long-term expansion in vitro and genera...
https://www.cell.com/cell/fulltext/S0092-8674(24)01254-6
1
43
15
reposted by
Günter Schneider
Itai Yanai
about 1 year ago
What were the most inspiring 2024 discoveries in cancer? Cancer Discovery asked me, Katherine Aird, Aadel Chaudhuri, Jennifer Guerriero, Shiri Gur-Cohen, Benjamin Izar, Brittany Jenkins, Delphine Merino, Alejo Rodriguez-Fraticelli & Shensi Shen, & here's what we said
aacrjournals.org/cancerdiscov...
1
87
37
reposted by
Günter Schneider
Dan Nomura
about 1 year ago
From Dikic/Sorrell labs:
www.cell.com/cell-chemica...
loading . . .
An engineered cereblon optimized for high throughput screening and molecular glue discovery
Due to challenges in studying molecular interactions of CRBN, identification of CRBN based molecular glues has remained underexplored. Here, Bailey et al designed an easy-to-handle CRBN construct and ...
https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(24)00460-4?utm_source=dlvr.it
0
17
2
reposted by
Günter Schneider
Carmelo Ferrai
about 1 year ago
EpiSci - 🧪 - 🧬
@jcellsci.bsky.social
@jcellbiol.bsky.social
Jessica Sacco, Esther Gomez and colleagues find that chemomechanical regulation of EZH2 localisation controls EMT. Highlight:
journals.biologists.com/jcs/article/13…
Article
: journals.biologists.com/jcs/article/13
0
5
2
reposted by
Günter Schneider
Akis (Argyris) Papantonis
about 1 year ago
We are extremely happy at the UMG to be supported by the EKFS for establishing a postdoctoral college bringing ambitious basic scientists into clinical research. Application details for our “Genomic responses to disease plasticity” program to follow soon!
sohub.io/rl2y
loading . . .
Förderung naturwissenschaftlicher Forschung und interdisziplinärer Kooperation in der Medizin
Else Kröner Medical Scientist Kollegs in Höhe von 3,3 Millionen Euro in den Bereichen der Immunologie, Genomik und Inflammation vergeben
https://sohub.io/rl2y
3
11
3
It was great meeting everyone last week at TUM. We had an important discussion on strategies to target pancreatic cancer cells and enhance immune-assisted eradication. I'm excited to continue working with all of you!
about 1 year ago
0
0
0
reposted by
Günter Schneider
Dan Nomura
about 1 year ago
New paper out of Katya Vinogradova’s lab!
www.sciencedirect.com/science/arti...
loading . . .
Covalent targeting of splicing in T cells
Despite significant interest in therapeutic targeting of splicing, few chemical probes are available for the proteins involved in splicing. Here, we s…
https://www.sciencedirect.com/science/article/pii/S2451945624004458
1
57
14
reposted by
Günter Schneider
Manuel Kaulich
about 1 year ago
I’ll be pitching a Mosbacher Kolloquium at the next annual meeting of the German Society for Biochemistry and Molecular Biology (GBM). The topic will be „Advances in gene regulation, editing, and medicine“. Anything that you’d like to be highlighted?
gbm-online.de/en/the-gbm-2...
loading . . .
GBM-Startseite - Homepage of the German Society for Biochemistry and Molecular Biology (GBM, Gesellschaft für Biochemie und Molekularbiologie e.V.)
The German Society for Biochemistry and Molecular Biology - GBM is an interest representation for scientists. Contents are scientific meetings, study groups (Fachgruppen), journals Biospektrum and Bio...
https://gbm-online.de/en/the-gbm-2.html
0
0
2
reposted by
Günter Schneider
Anirban Maitra
over 1 year ago
Dear Colleagues The journal Carcinogenesis has released a special issue on
#PancreaticCancer
research in honor of Perwez Hussain. It contains several open access reviews and Perwez’s last article. Please read and share. He is deeply missed.
academic.oup.com/carcin/issue...
loading . . .
Volume 45 Issue 11 | Carcinogenesis | Oxford Academic
Publishes original contributions on all aspects of cancer research. Subjects covered include biology, genetics and epigenetics, cancer biomarkers and molecular epidemiology, inflammation, microenviron...
https://academic.oup.com/carcin/issue/45/11
0
41
13
you reached the end!!
feeds!
log in